Thymosin Alpha-1 & Thymulin Blend

Thymosin Alpha-1 & Thymulin Blend has no established direct evidence for the exact combined product. Thymosin alpha-1 has a stronger clinical literature than many research peptides, including randomized trials in chronic hepatitis B and a large phase 3 sepsis trial that found no clear 28-day mortality benefit. Thymulin evidence is more limited and older, focused on its role as a thymic peptide hormone involved in immune and neuroendocrine regulation, with preclinical work suggesting effects on inflammatory cytokines. These two components both relate to thymic or immune signaling, but that does not establish a combined effect, clinical usefulness, dosing, or safety profile.

Thymosin Alpha-1 Trials

Thymosin alpha-1 was evaluated in randomized chronic hepatitis B trials, including a multicenter phase 3 placebo-controlled study ^[1][2].

Sepsis Trial Boundary

A large multicenter phase 3 sepsis trial did not show clear evidence that thymosin alpha-1 reduced 28-day all-cause mortality ^[3].

Thymulin Context

Thymulin has been described as a thymic peptide involved in immunomodulation, with animal inflammation work reporting cytokine effects ^[4][5].

Blend Safety Not Established

No safety profile is established for the exact Thymosin Alpha-1 and Thymulin blend.

FDA and Evidence Caveats

FDA states safety-related information for compounded thymosin alpha-1 is inadequate to understand the extent of safety issues raised by the proposed compounded drug, and thymulin support is mostly mechanistic or preclinical ^[4][5][6].